JSPR News and Press, Jasper Therapeutics Inc. From 02/06/24

REDWOOD CITY, Calif., Feb. 06, 2024 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (“Jasper”), a clinical-stage biotechnology company focused on developing novel antibody therapies targeting c-Kit (CD117) to address diseases such as chronic spontaneous urticaria (CSU) ...

REDWOOD CITY, Calif., Feb. 05, 2024 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a biotechnology company focused on development of briquilimab, a novel antibody therapy targeting c-Kit (CD117) in mast cell driven diseases such as chronic spontaneous urticaria (CSU) and c...

2024-02-05 01:50:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

2024-01-25 09:58:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

2024-01-18 13:35:16 ET More on Mid-day movers & stocks. Phunware, Inc. (PHUN) Q3 2023 Earnings Call Transcript Jasper Therapeutics to effect 1-for-10 reverse stock split Phunware Q3 2023 Earnings Preview Seeking Alpha’s Quant Rating on Jasper Thera...

- EU Clinical Trials authorized for Phase 1b/2a SPOTLIGHT and BEACON studies of briquilimab in CIndU and CSU, respectively - Patient enrollment in Phase 1b/2a SPOTLIGHT study of briquilimab in CIndU expected to commence in first quarter of 2024, initial data readout in second half of 20...

2024-01-03 08:02:08 ET Jasper Therapeutics Inc (JSPR) announced stock split at a ratio of 1-for-10 on 2024-01-04 ... Full story available on KlickAnalytics.com

2024-01-02 08:09:07 ET More on Jasper Therapeutics Seeking Alpha’s Quant Rating on Jasper Therapeutics Historical earnings data for Jasper Therapeutics Financial information for Jasper Therapeutics For further details see: Jasper Therapeutics to ef...

REDWOOD CITY, Calif., Jan. 02, 2024 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a biotechnology company focused on development of briquilimab, a novel antibody therapy targeting c-Kit (CD117) in mast cell-driven diseases such as chronic spontaneous urticaria (CSU) and c...

REDWOOD CITY, Calif., Dec. 10, 2023 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a biotechnology company focused on the development of briquilimab, a novel antibody therapy targeting c-Kit (CD117) to address mast cell driven diseases such as chronic spontaneous urticaria...